var data={"title":"Ampicillin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ampicillin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5637?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">see &quot;Ampicillin: Drug information&quot;</a> and <a href=\"topic.htm?path=ampicillin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ampicillin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134956\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ampicillin for Injection;</li>\n      <li>Apo-Ampi;</li>\n      <li>Novo-Ampicillin;</li>\n      <li>Nu-Ampi</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045166\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Penicillin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11432528\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Weight-directed dosing (Bradley 2016; <i>Red Book</i> [AAP 2015]): IM, IV:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Body</p>\n            <p style=\"text-indent:0em;\">Weight</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Postnatal</p>\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Dose</p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td rowspan=\"3\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;1 kg</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 14 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">50 to 75 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">15 to 28 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">75 mg/kg/dose every 12 hours</p>\n            <p style=\"text-indent:0em;margin-top:2em;\">\n              <b>or</b></p>\n            <p style=\"text-indent:0em;margin-top:2em;\">50 mg/kg/dose every 8 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">1 to 2 kg</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 28 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">75 mg/kg/dose every 12 hours</p>\n            <p style=\"text-indent:0em;margin-top:2em;\">\n              <b>or</b></p>\n            <p style=\"text-indent:0em;margin-top:2em;\">50 mg/kg/dose every 8 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"3\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;2 kg</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 8 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 28 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 6 to 8 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">29 to 60 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 6 hours</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Age-directed dosing (Tremoulet 2014): IM, IV:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Gestational</p>\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Postnatal</p>\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Dose</p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;34 weeks</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 28 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">75 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;34 weeks</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;28 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 8 hours</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Group B streptococcal bacteremia (presumed or proven)</b> (<i>Red Book </i>[AAP 2015]): <b>Note:</b> Treatment of bacteremia without a defined focus should be for at least 10 days: IM, IV:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Body</p>\n            <p style=\"text-indent:0em;\">Weight</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Postnatal</p>\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Dose</p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;1 kg</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;14 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">100 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">15 to 28 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 8 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">1 to 2 kg</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">100 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 28 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 8 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;2 kg</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">100 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 28 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 6 hours</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Group B streptococcal meningitis:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PNA &le;7 days: 200 to 300 mg/kg/<b>day</b> divided every 8 hours or 300 mg/kg/day divided every 6 hours have been suggested; continue for at least 14 days if uncomplicated; (Bradley 2016; <i>Red Book</i> [AAP 2015]; IDSA [Tunkel 2004])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PNA &gt;7 days: 300 mg/kg/<b>day</b> divided every 6 hours for at least 14 days if uncomplicated (Bradley 2016; <i>Red Book</i> [AAP 2015]; IDSA [Tunkel 2004])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical prophylaxis:</b> IV: 50 mg/kg as a single dose (<i>Red Book</i> [AAP 2015])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045158\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">see &quot;Ampicillin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection</b> (<i>Red Book</i> [AAP 2015]): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infection:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 50 to 100 mg/kg/<b>day</b> divided every 6 hours; maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM, IV: 100 to 150 mg/kg/<b>day</b> divided every 6 hours; maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infection: IM, IV: 200 to 400 mg/kg/<b>day</b> divided every 6 hours; maximum daily dose: 12 <b>g/day </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Community-acquired pneumonia (CAP)</b> (IDSA/PIDS [Bradley 2011]): Infants &gt;3 months, Children, and Adolescents: <b>Note:</b> May consider addition of vancomycin or clindamycin to empiric therapy if community-acquired MRSA suspected. In children &ge;5 years, a macrolide antibiotic should be added if atypical pneumonia cannot be ruled out.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Empiric treatment or <i>S. pneumoniae</i> (MICs for penicillin &le;2 mcg/mL) or <i>H. influenzae</i> (beta-lactamase negative) in fully immunized patients: IV: 150 to 200 mg/kg/<b>day</b> divided every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Group A <i>Streptococcus</i>: IV: 200 mg/kg/<b>day</b> divided every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. pneumoniae</i> (MICs for penicillin &ge;4 mcg/mL): IV: 300 to 400 mg/kg/<b>day</b> divided every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: Children and Adolescents: IV: 200 to 300 mg/kg/day divided every 4 to 6 hours; maximum daily dose: 12 g/<b>day</b>; use in combination with other antibiotics for at least 4 weeks; some organisms may require longer duration (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prophylaxis: <b>Note: </b>AHA guidelines (Baltimore 2015) limit the use of prophylactic antibiotics to patients at the highest risk for infective endocarditis (IE) or adverse outcomes (eg, prosthetic heart valves, patients with previous IE, unrepaired cyanotic congenital heart disease, repaired congenital heart disease with prosthetic material or device during first 6 months after procedure, repaired congenital heart disease with residual defects at the site or adjacent to site of prosthetic patch or device, and heart transplant recipients with cardiac valvulopathy):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dental or oral procedures or respiratory tract procedures (eg, tonsillectomy, adenoidectomy):</i> Infants, Children, and Adolescents: IV, IM: 50 mg/kg within 30 to 60 minutes before procedure; maximum dose: 2,000 mg/dose. Intramuscular (IM) injections should be avoided in patients who are receiving anticoagulant therapy. In these circumstances, orally administered regimens should be used whenever possible. Intravenously (IV) administered antibiotics should be used for patients who are unable to tolerate or absorb oral medications (Wilson 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection, complicated:</b> Infants, Children, and Adolescents: IV: 200 mg/kg/<b>day</b> divided every 6 hours; maximum single dose: 2,000 mg; maximize doses if undrained abdominal abscesses (IDSA [Solomkin 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis:</b>  Infants, Children, and Adolescents: IV: 200 to 400 mg/kg/<b>day</b> divided every 6 hours; maximum daily dose: 12 <b>g/day</b> (<i>Red Book</i> [AAP 2015]; IDSA [Tunkel 2004])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis (CAPD)</b> Limited data available: Infants, Children, and Adolescents:  Intraperitoneal: 125 mg per liter of dialysate for 2 weeks (ISPD [Warady 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical prophylaxis:</b> Infants, Children, and Adolescents: IV: 50 mg/kg 30 to 60 minutes prior to procedure; may repeat in 2 hours if lengthy procedure or excessive blood loss; maximum single dose: 2,000 mg (ASHP/IDSA [Bratzler 2013]; <i>Red Book</i>  [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 250 to 500 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV: 1,000 to 2,000 mg every 4 to 6 hours or 50 to 250 mg/kg/day in divided doses (maximum: 12 g/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: IV: 2,000 mg every 4 hours in combination with other antibiotics; concomitant antibiotic choice and duration is based on organism and valve type (AHA [Baddour 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prophylaxis:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dental, oral, or respiratory tract procedures:</i> IM, IV: 2,000 mg within 30 to 60 minutes prior to procedure in patients not allergic to penicillin and unable to take oral amoxicillin. IM injections should be avoided in patients who are receiving anticoagulant therapy. In these circumstances, orally administered regimens should be given whenever possible. Intravenously administered antibiotics should be used for patients who are unable to tolerate or absorb oral medications. <b>Note:</b> American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur (AHA [Wilson 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Genitourinary and gastrointestinal tract procedures:</i> IM, IV: <b>Note:</b> Routine prophylaxis for GI/GU procedures is no longer recommended by the AHA. Consider only in patients with the highest risk of adverse outcome from endocarditis (eg, prosthetic heart valve, previous endocarditis, some categories of congenital heart disease, cardiac valvulopathy in cardiac transplant patients) who have an established GI or GU enterococcal infection or for those already receiving antibiotic therapy to prevent a wound infection or sepsis associated with a GI or GU procedure in which enterococcal coverage is desired (AHA [Wilson 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">High-risk patients: 2,000 mg within 30 minutes prior to procedure, followed by ampicillin 1,000 mg (or amoxicillin 1,000 mg orally) 6 hours later; must be used in combination with gentamicin (Dajani 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Moderate-risk patients: 2,000 mg within 30 minutes prior to procedure (Dajani 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Genitourinary or gastrointestinal infections:</b> Oral, IM, IV: 500 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b> Group B streptococcus (maternal dose for neonatal prophylaxis):</b> IV: 2,000 mg initial dose, then 1,000 mg every 4 hours until delivery (CDC 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Respiratory tract infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 250 mg 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV: 250 to 500 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sepsis/meningitis:</b> IM, IV: <b>Note: </b>administer doses IV initially; IM may be used later in therapy course: 150 to 200 mg/kg/day divided every 3 to 4 hours (range: 6 to 12 g/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, the following adjustments have been recommended (Aronoff 2007). <b>Note:</b> Renally adjusted dose recommendations are based on doses of 100 to 200 mg/kg/day divided every 6 hours: IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 35 to 50 mg/kg/dose every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 35 to 50 mg/kg/dose every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 35 to 50 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis: 35 to 50 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD):  35 to 50 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): 35 to 50 mg/kg/dose every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, the following adjustments have been recommended (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;50 mL/minute: Administer every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 50 mL/minute: Administer every 6 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute: Administer every 12 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (20% to 50%): IV: 1 to 2 g every 12 to 24 hours (Heintz 2009). <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD): 250 mg every 12 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CVVH: Loading dose of 2,000 mg followed by 1,000 to 2,000 mg every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CVVHD: Loading dose of 2,000 mg followed by 1,000 to 2,000 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CVVHDF: Loading dose of 2,000 mg followed by 1,000 to 2,000 mg every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134931\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg [DSC], 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as sodium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg (1 ea); 250 mg (1 ea); 500 mg (1 ea); 1 g (1 ea); 2 g (1 ea); 10 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as sodium [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg (1 ea); 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as sodium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea); 10 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as sodium [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 g (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg/5 mL (100 mL [DSC], 200 mL [DSC]); 250 mg/5 mL (100 mL [DSC], 200 mL [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134915\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045170\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer around-the-clock to promote less variation in peak and trough serum levels. Administer on an empty stomach (ie, 1 hour prior to or 2 hours after meals) to increase total absorption; shake suspension well before using</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Inject deep IM into a large muscle mass</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV push: Doses &le;500 mg should be administered over 3 to 5 minutes; doses &gt;500 mg should be administered over 10 to 15 minutes; rapid administration has been associated with seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent IV infusion: Infuse over 10 to 15 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Some penicillins (eg, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides in vitro. This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy in vivo, particularly in the setting of profound renal impairment; however, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2508661\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Capsules: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral suspension: Store dry powder at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Once reconstituted, oral suspension is stable for 14 days under refrigeration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solutions for IM or direct IV should be used within 1 hour.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stability of parenteral admixture in NS at 25&deg;C (77&deg;F) is 8 hours (concentrations up to 30 mg/mL) and at 4&deg;C (39&deg;F) is 24 hours (concentration of 30 mg/mL) or 48 hours (concentrations up to 20 mg/mL). Protect from freezing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045169\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of susceptible respiratory, gastrointestinal, and urinary tract infections; bacterial meningitis, septicemia, and endocarditis [FDA approved in pediatric patients (age not specified) and  adults]; susceptible organisms may include streptococci, pneumococci, enterococci, nonpenicillinase-producing staphylococci, <i>Listeria</i>, meningococci; some strains of <i>H. influenzae</i>, <i>P. mirabilis</i>, <i>Salmonella</i>, <i>Shigella</i>, <i>E. coli</i>, <i>Enterobacter</i>, and <i>Klebsiella</i>; has also been used as empiric  therapy for neonatal sepsis or meningitis, endocarditis prophylaxis, prophylaxis of peritonitis in patients with peritoneal dialysis catheters undergoing invasive dental procedures, and treatment of exit site or tunnel infections in patients with peritoneal dialysis catheters</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135014\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ampicillin may be confused with aminophylline</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135011\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Brain disease (penicillin-induced), glossalgia, seizure, sore mouth</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema multiforme, exfoliative dermatitis, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Appearance of a rash should be carefully evaluated to differentiate (if possible) nonallergic ampicillin rash from hypersensitivity reaction. Incidence is higher in patients with viral infection, <i>Salmonella</i> infection, lymphocytic leukemia, or patients that have hyperuricemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, enterocolitis, glossitis, melanoglossia, nausea, oral candidiasis, pseudomembranous colitis, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, anemia, eosinophilia, hemolytic anemia, immune thrombocytopenia, leukopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Serum sickness-like reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Interstitial nephritis (rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Stridor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Dysgeusia (Syed 2016)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134938\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, anaphylaxis) to ampicillin, any component of the formulation, or other penicillins; infections caused by penicillinase-producing organisms </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134919\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity/anaphylactoid reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity or a history of sensitivity to multiple allergens. Serious anaphylactoid reactions require emergency treatment and airway management.  Appropriate treatments must be readily available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Rash: Appearance of a rash should be carefully evaluated to differentiate a nonallergic ampicillin rash from a hypersensitivity reaction; rash occurs in 5% to 10% of children and is a generalized dull red, maculopapular rash, generally appearing 3 to 14 days after the start of therapy. It normally begins on the trunk and spreads over most of the body. It may be most intense at pressure areas, elbows, and knees. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>Clostridium difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infectious mononucleosis: A high percentage of patients with infectious mononucleosis have developed rash during therapy; ampicillin-class antibiotics not recommended in these patients. Rash (generalized maculopapular and pruritic) usually appears 7 to 10 days after initiation and usually resolves within a week of discontinuation. It is not known whether these patients are truly allergic to ampicillin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298748\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134924\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12683&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: May enhance the potential for allergic or hypersensitivity reactions to Ampicillin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atenolol: Ampicillin may decrease the bioavailability of Atenolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroquine: May decrease the serum concentration of Ampicillin. Management: Chloroquine prescribing information recommends separating administration of ampicillin and chloroquine by at least 2 hours to minimize any potential negative impact of chloroquine on ampicillin bioavailability.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Ampicillin. Management: Administer oral ampicillin at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Penicillins. Management: Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins if probenecid is initiated or the dose is increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134951\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food decreases ampicillin absorption rate; may decrease ampicillin serum concentration. Management: Take at equal intervals around-the-clock, preferably on an empty stomach (30 minutes before or 2 hours after meals). Maintain adequate hydration, unless instructed to restrict fluid intake.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134927\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134941\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Ampicillin crosses the placenta, providing detectable concentrations in the cord serum and amniotic fluid (Bolognese 1968; Fisher 1967; MacAulay 1966). Maternal use of ampicillin has generally not resulted in an increased risk of birth defects (Aselton 1985; Czeizel 2001b; Heinonen 1977; Jick 1981; Puh&oacute; 2007). Ampicillin is recommended for use in pregnant women for the management of preterm prelabor rupture of membranes (PROM) and for the prevention of early-onset group B streptococcal (GBS) disease in newborns. Ampicillin may also be used in certain situations prior to vaginal delivery in women at high risk for endocarditis (ACOG 120 2011; ACOG 188 2018; ACOG 485 2011; CDC [RR-10] 2010).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The volume of distribution of ampicillin is increased during pregnancy and the half-life is decreased. As a result, serum concentrations in pregnant patients are approximately 50% of those in nonpregnant patients receiving the same dose. Higher doses may be needed during pregnancy. Although oral absorption is not altered during pregnancy, oral ampicillin is poorly absorbed during labor (Philipson 1977; Philipson 1978; Wasz-H&ouml;ckert 1970).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045165\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">With prolonged therapy, monitor renal, hepatic, and hematologic function periodically; observe for change in bowel frequency; observe for signs of anaphylaxis with first dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134918\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134937\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: 50% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Into bile; penetration into CSF occurs with inflamed meninges only</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Neonates: 10%; Adults: 15% to 18% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA 2 to 7 days: 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA 8 to 14 days: 2.8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA 15 to 30 days: 1.7 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adults: 1 to 1.8 hours (Bergan 1979)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anuric patients: 8 to 20 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak serum concentration: Oral: Within 1 to 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&sim;90%, unchanged within 24 hours); feces </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045174\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Sodium content: Oral  suspension (250 mg/5 mL, 5 mL): 10 mg (0.4 mEq); parenteral (1 g): 66.7 mg (3 mEq)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422187\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Ampicillin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $58.89</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Ampicillin Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $7.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $13.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g (1): $84.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (1): $5.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (1): $2.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $3.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Ampicillin Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $16.37</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $8.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g (1): $84.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134943\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acipillin (BD);</li>\n      <li>Alphacin (NZ);</li>\n      <li>Alphapen (MX);</li>\n      <li>Ambiopi (ID);</li>\n      <li>Amcillin (KR);</li>\n      <li>Amcopen (PK);</li>\n      <li>Amfipen (AE, BH, CY, EG, GB, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Amicap (BD);</li>\n      <li>Amillin (MY);</li>\n      <li>Amipenix (JP);</li>\n      <li>Ampecu (EC);</li>\n      <li>Ampen (VE);</li>\n      <li>Ampi-1 (PH);</li>\n      <li>Ampibex (EC);</li>\n      <li>Ampiblan (CO);</li>\n      <li>Ampicil (BR);</li>\n      <li>Ampicilin (ET);</li>\n      <li>Ampicilina (EC);</li>\n      <li>Ampicillin (PL);</li>\n      <li>Ampicin (PH);</li>\n      <li>Ampiclin (PH);</li>\n      <li>Ampiclox (SG);</li>\n      <li>Ampicyn (AU, TH);</li>\n      <li>Ampidar (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ampiger (BR);</li>\n      <li>Ampilag (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Ampilin (IN);</li>\n      <li>Ampillin (MY);</li>\n      <li>Ampimedin (PY);</li>\n      <li>Ampina (LK);</li>\n      <li>Ampipen (IN, ZA);</li>\n      <li>Ampipharm (JO);</li>\n      <li>Ampitenk (AR);</li>\n      <li>Ampitrex (PH);</li>\n      <li>Ampivral (CO);</li>\n      <li>Ampliblan (CO);</li>\n      <li>Ampolin (TW);</li>\n      <li>Amsapen (MX);</li>\n      <li>Ancillin (TW);</li>\n      <li>Antallpen (LB);</li>\n      <li>Ascillin (ET);</li>\n      <li>Austrapen (AU);</li>\n      <li>Axum (HU);</li>\n      <li>Binotal (AT, BR, CO, MX, UY);</li>\n      <li>Biocil (MY);</li>\n      <li>Bridopen (PH);</li>\n      <li>Britapen (ES);</li>\n      <li>Brupen (MX);</li>\n      <li>Camicil (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Dancin (PH);</li>\n      <li>Dhacillin (MY);</li>\n      <li>Dibacilina (MX);</li>\n      <li>Dinpen (PH);</li>\n      <li>Doktacillin (SE);</li>\n      <li>Duacillin (MY);</li>\n      <li>Eurocin (PH);</li>\n      <li>Excillin (PH);</li>\n      <li>Extrapen (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Ficillin (BD);</li>\n      <li>Flamicina (MX);</li>\n      <li>Gobemicina (ES);</li>\n      <li>Gobemicina Retard (CR, DO, HN, NI, PA, SV);</li>\n      <li>Gramcil (PH);</li>\n      <li>Ibimycin (AU);</li>\n      <li>Intramed (ZA);</li>\n      <li>Iwacillin (JP);</li>\n      <li>Maeline (LK);</li>\n      <li>Magnapen (PE);</li>\n      <li>Marovilina (MX);</li>\n      <li>Maxipen (CO);</li>\n      <li>Meprizna (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Microcilin (PH);</li>\n      <li>Nimpicillin (LK);</li>\n      <li>Norcipen (JO);</li>\n      <li>Novencil (EC);</li>\n      <li>Omnipen (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, MX, OM, QA, SA, SY, YE);</li>\n      <li>Pamecil (BF, BJ, CI, ET, GH, GM, GN, JO, KE, LR, LV, MA, ML, MR, MU, MW, MY, NE, NG, RO, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Panacta (PH);</li>\n      <li>Pelitin (TW);</li>\n      <li>Penbrex (KR);</li>\n      <li>Penbritin (AE, BF, BH, BJ, CI, CR, CY, DO, EG, ET, GH, GM, GN, GT, HN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, OM, PA, PE, QA, SA, SC, SD, SL, SN, SV, SY, TN, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Penibrin (IL);</li>\n      <li>Penodil (TR);</li>\n      <li>Pentrexyl (BE, BF, BJ, CI, DK, ET, GB, GH, GM, GN, GR, IT, KE, LR, LU, MA, ML, MR, MU, MW, MX, NE, NG, NO, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Petercillin (ZA);</li>\n      <li>Polypen (PH);</li>\n      <li>Primapen (ID);</li>\n      <li>Promecilina (MX);</li>\n      <li>Pulmosterin Retard (CR, DO, HN, NI, PA, SV);</li>\n      <li>Radiocillina (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Reichlin (HK);</li>\n      <li>Rimacillin (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PR, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZM, ZW);</li>\n      <li>Roscillin (IN, LK);</li>\n      <li>Sanpicillin (ID);</li>\n      <li>Semicillin (HN, HU);</li>\n      <li>Shacillin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Silina (ET);</li>\n      <li>Standacillin (AE, AT, BG, BH, CY, EE, EG, HU, IQ, IR, JO, KW, LB, LY, OM, QA, RO, SA, SY, YE);</li>\n      <li>Standcillin (MY);</li>\n      <li>Synthocilin (IN);</li>\n      <li>Syntocil (TR);</li>\n      <li>Totapen (FR);</li>\n      <li>Tricil (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Trifalicina (AR);</li>\n      <li>Trilaxin (PH);</li>\n      <li>Ultracillin (AE);</li>\n      <li>Viccillin (ID, TH);</li>\n      <li>Vidopen (GB);</li>\n      <li>Virucil (CO);</li>\n      <li>Winpicillin (TW);</li>\n      <li>Z-Cil (ET);</li>\n      <li>Zampicillin (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, &quot;ACOG Practice Bulletin No. 120: Use of Prophylactic Antibiotics in Labor and Delivery,&quot; <i>Obstet Gynecol</i>, 2011, 117(6):1472-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/21606770/pubmed\" target=\"_blank\" id=\"21606770\">21606770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists Committee on Obstetric Practice, &quot;ACOG Committee Opinion No. 485: Prevention of Early-Onset Group B Streptococcal Disease in Newborns,&quot; <i>Obstet Gynecol</i>, 2011, 117(4):1019-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/21422882/pubmed\" target=\"_blank\" id=\"21422882\">21422882</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists. Practice bulletin no. 160: premature rupture of membranes. <i>Obstet Gynecol</i>. 2016;127(1):e39-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/26695586 /pubmed\" target=\"_blank\" id=\"26695586 \">26695586 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ampicillin injection [prescribing information]. Lake Forest, IL: Hospira, Inc; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007, 55, 149.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aselton P, Jick H, Milunsky A, et al, &quot;First-Trimester Drug Use and Congenital Disorders,&quot; <i>Obstet Gynecol</i>, 1985, 65(4):451-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/3982720/pubmed\" target=\"_blank\" id=\"3982720\">3982720</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association [published correction appears in <i>Circulation</i>. 2015;132(17):e215. <i>Circulation</i>. 2015;132(15):1435-1486.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/26373316/pubmed\" target=\"_blank\" id=\"26373316\">26373316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boguniewicz M and Leung DY, &ldquo;Hypersensitivity Reactions to Antibiotics Commonly Used in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1995, 14(3):221-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/7761188/pubmed\" target=\"_blank\" id=\"7761188\">7761188</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bolognese RJ, &quot;Ampicillin: Transfer Into Fetus and Amniotic Fluid,&quot; <i>Rocky Mt Med J</i>, 1968, 65(8):72-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/5667909/pubmed\" target=\"_blank\" id=\"5667909\">5667909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 22nd ed. American Academy of Pediatrics; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brown RD, Campoli-Richards DM, &ldquo;Antimicrobial Therapy in Neonates, Infants, and Children,&rdquo; <i>Clin Pharmacokinet</i>, 1989, 17(Suppl 1):105-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/2692934 /pubmed\" target=\"_blank\" id=\"2692934 \">2692934 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease, revised guidelines from CDC, 2010. <i>MMWR Recomm Rep</i>. 2010; 59(RR-10):1-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/21088663/pubmed\" target=\"_blank\" id=\"21088663\">21088663</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow MS, Quintiliani R, and Nightingale CH, &quot;<i>In Vivo</i> Inactivation of Tobramycin by Ticarcillin. A Case Report,&quot; <i>JAMA</i>, 1982, 247(5):658-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/6798229/pubmed\" target=\"_blank\" id=\"6798229\">6798229</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Czeizel AE, Rockenbauer M, S&oslash;rensen HT, et al, &quot;A Population-Based Case-Control Teratologic Study of Ampicillin Treatment During Pregnancy,&quot; <i>Am J Obstet Gynecol</i>, 2001b, 185(1):140-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/11483918/pubmed\" target=\"_blank\" id=\"11483918\">11483918</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. <i>JAMA</i>. 1997;277(22):1794-1801.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/9178793 /pubmed\" target=\"_blank\" id=\"9178793 \">9178793 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daly JS, Dodge RA, Glew RH, et al, &quot;Effect of Time and Temperature on Inactivation of Aminoglycosides by Ampicillin at Neonatal Dosages,&quot; <i>J Perinatol</i>, 1997, 17(1):42-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/9069064/pubmed\" target=\"_blank\" id=\"9069064\">9069064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farchione LA, &quot;Inactivation of Aminoglycosides by Penicillins,&quot; <i>J Antimicrob Chemother</i>, 1982, 8(Suppl A):27-36.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fisher AM and Smith MR, &quot;The Prophylactic Use of Ampicillin and Its Trans-Placental Passage After Amniotomy,&quot; <i>J Obstet Gynaecol Br Commonw</i>, 1967, 74(6):855-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/6066463/pubmed\" target=\"_blank\" id=\"6066463\">6066463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heinonen OP, Slone D, and Shapiro S, &quot;Birth Defects and Drugs in Pregnancy,&quot; Publishing Sciences Group, Inc, Littleton, MA, 1977.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, and Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jick H, Holmes LB, Hunter JR, et al, &quot;First-Trimester Drug Use and Congenital Disorders,&quot; <i>JAMA</i>, 1981, 246(4):343-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/7241780/pubmed\" target=\"_blank\" id=\"7241780\">7241780</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacAulay MA, Abou-Sabe M, and Charles D, &quot;Placental Transfer of Ampicillin,&quot;<i> Am J Obstet Gynecol</i>, 1966, 96(7):943-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/5928458/pubmed\" target=\"_blank\" id=\"5928458\">5928458</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Philipson A, &quot;Pharmacokinetics of Ampicillin During Pregnancy,&quot; <i>J Infect Dis</i>, 1977, 136(3):370-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/903675/pubmed\" target=\"_blank\" id=\"903675\">903675</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Philipson A. Plasma levels of ampicillin in pregnant women following administration of ampicillin and pivampicillin. <i>Am J Obstet Gynecol</i>. 1978;130(6):674-683.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Puh&oacute; EH, Szunyogh M, M&eacute;tneki J, et al, &quot;Drug Treatment During Pregnancy and Isolated Orofacial Clefts in Hungary,&quot; <i>Cleft Palate Craniofac J</i>, 2007, 44(2):194-202.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/17328645/pubmed\" target=\"_blank\" id=\"17328645\">17328645</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shaffer CL, Davey AM, Ransom JL, et al, &quot;Ampicillin-Induced Neurotoxicity in Very-Low-Birth-Weight Neonates,&quot; <i>Ann Pharmacother</i>, 1998, 32(4):482-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/9562146/pubmed\" target=\"_blank\" id=\"9562146\">9562146</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &quot;Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/PMID:20034345[PubMed - indexed for MEDLINE] Free full text /pubmed\" target=\"_blank\" id=\"PMID:20034345[PubMed - indexed for MEDLINE] Free full text \">PMID:20034345[PubMed - indexed for MEDLINE] Free full text </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tremoulet A, Le J, Poindexter B, et al. Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design. <i>Antimicrob Agents Chemother</i>. 2014;58(6):3013-3020.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/24614374 /pubmed\" target=\"_blank\" id=\"24614374 \">24614374 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al, &quot;Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update,&quot; <i>Perit Dial Int</i>, 2012, (32 Suppl 2):S32-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wasz-H&ouml;ckert O, Nummi S, Vuopala S, et al, &quot;Transplacental Passage of Azidocillin, Ampicillin and Penicillin G During Early and Late Pregnancy,&quot; <i>Acta Paediatr Scand Suppl</i>, 1970, 206(Suppl 206):109.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/5276929/pubmed\" target=\"_blank\" id=\"5276929\">5276929</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo; <i>Circulation</i>, 2007, 115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ampicillin-pediatric-drug-information/abstract-text/17446442/pubmed\" target=\"_blank\" id=\"17446442\">17446442</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12683 Version 171.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F134956\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045166\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11432528\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045158\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F134931\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F134915\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045170\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F2508661\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045169\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F135014\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F135011\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F134938\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F134919\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298748\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F134924\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F134951\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F134927\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F134941\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045165\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F134918\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F134937\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1045174\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422187\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F134943\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12683|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">Ampicillin: Drug information</a></li><li><a href=\"topic.htm?path=ampicillin-patient-drug-information\" class=\"drug drug_patient\">Ampicillin: Patient drug information</a></li></ul></div></div>","javascript":null}